NCT03316599 2021-08-03
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
Clinical Trials
7 trialsNCT02109627 2020-03-24
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
University of California, San Francisco
Phase 1 Terminated
NCT02277197 2019-04-18
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Pittsburgh
Phase 1 Completed
NCT02277184 2017-11-13
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
University of Pittsburgh
Phase 1 Terminated
NCT00725634 2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00969410 2012-04-12
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT01189513 2012-02-20
SCH-900105 in Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1 Withdrawn